Geron Corp.  (GERN) Trade Now »     Rate GERN  -  Discuss GERN  -  Add to Watch List        

Regenerative Medicine: The Next Frontier for Big Pharma

An article last week at the WSJ Health Blog outlined plans by Pfizer (PFE) to begin putting its billions of dollars in cash to use in the emerging field of regenerative medicine and stem cell therapies. Also, an article on Bloomberg identifies GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Novartis (NVS), and Roche (RHHBY) as other healthcare giants as active in regenerative medicine through investments and partnerships.

The move by these healthcare mega-caps comes at a time when credit

Filed under: Newsletters, Stocks to Buy

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

"If Barack Obama wins the presidency, one under-the-radar play would be embryonic stem cell research; Geron (NASDAQ: GERN) is the current leader in embryonic stem cell research among publicly traded companies," explains trading and investing expert Bill Martin in his BullMarket.com.

"Embryonic stem cell research in the U.S. is not restricted in any way, as is often popularly believed in this hotly cont

Filed under: Microsoft (MSFT), Apple Inc (AAPL), Time Warner (TWX), India, China, Brazil, Newsletters, Mutual funds, Comcast Cl'A' (CMCSA), Merck and Co (MRK), Canada, Cardinal Health (CAH), Barclays plc ADS (BCS), EOG Resources (EOG), Presidential elections, Commodities, Oil, Agriculture, Stocks to Buy, Technology, General Dynamics Corp (GD), Israel, Green Stocks, Northrop Grumman (NOC)

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

Based on their campaign promises and party platforms

January 30th , 2008

SpeculatingStocks.com Stock Pick: Geron Corporation (GERN)

Stock Price: $5.15

Geron Corporation is a biopharmaceutical company developing therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes, and HIV/AIDS. The company is developing human embryonic stem cell therapies, including GRNOPC1, which contains oligodendroglial progenitor cells targeted for the treatment of spinal cord injury.

GERN could benefit from